Additionally, the same study demonstrated that letrozole was associated with a significantly reduced risk of disease - free survival event (DFS) in patients with luminal A and luminal B ILC concluding the magnitude of benefit from AI was greater in patients with ILC versus invasive ductal carcinomas.30 In our study we did not find any substantial differences between the effect of tamoxifen and AIs in PIK3CA mutated early-stage ILC patients when compared to patients who did not receive any adjuvant therapy. Here, PIK3CA is linked to invasive ductal breast carcinoma.